Xinbing Han

Principal Scientist, Immunonolgy, Diabetes, Obesity & Mash @Novo Nordisk

Cambridge, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jan 2023 — Present

Principal Scientist, Immunonolgy, Diabetes, Obesity & Mash @Novo Nordisk

View department →

Boston, MA, US

EDUCATION

N/A

Chinese Academy of Sciences, Beijing

Ph.D.

SKILLS

Real-Time PcrImmunologyAssay DevelopmentCell SignalingChipConfocal MicroscopyCytokinesHivTransfectionSignal TransductionMolecular BiologyInnate ImmunityChemokinesObesityPharmacologyTransgenic MiceLipid MetabolismMolecular CloningAnimal ModelsAtherosclerosisBiochemistryCardiovascular DiseaseProtein ExpressionRnaiMolecular & Cellular BiologyTranslational MedicineQpcrMacrophagesMolecular VirologyGpcrsAntibodiesMetabolic DiseaseEpigeneticsCellInflammationSite-Directed MutagenesisProtein KinasesBiomarker DiscoveryNeuroendocrinologyNuclear Receptors

ABOUT XINBING HAN

Drug Discovery & Preclinical Development: 10+ years of experience in drug discovery and preclinical development in the Pharma industry. Strong drug discovery and preclinical expertise in areas of autoimmune diseases, fibrosis, cardiovascular and metabolic diseases. Experience in identifying several targets in discovery, validating and advancing molecules to the clinic. Experience reviewing regulatory study reports & pharmacology protocols for small molecule programs. Published 33 articles in peer-reviewed journals and 2 book chapters. Matrix Team Experience: Closely worked with a team of 15+ scientists across four divisions. Strategized to achieve program milestones with teamwork skills. Research skills: Cytokines/chemokines, GPCRs, growth factors, receptors, kinases, enzymes, and transporters. Developed protein-protein interactions, biochemistry, in vitro & ex-vivo assays, translational research, and biomarkers. Strong experience in immunology, pharmacology, biochemistry, molecular and cell biology. Established preclinical cell and animal models in areas of autoimmune diseases/inflammation, cardiovascular and metabolic diseases. Worked on differentiated modalities including large and small molecules, cyclic peptides, chemically modified RNA, DNA plasmids, HSC and hiPSC, siRNA, shRNA, viral and non-viral delivery, cell and gene therapies.Collaboration: Successful collaborations with cross functional teams lead to the portfolio entry of the discovery program. Partnered with internal and external stakeholders, KOLs, academic institutions, and CROs, leading to the achievement of key deliverables.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Xinbing Han — Principal Scientist, Immunonolgy, Diabetes, Obesity & Mash at Novo Nordisk in Cambridge, MA, US | Unifers